Navigation Links
TopoTarget Successfully Buys Back Full Control of Belinostat
Date:4/22/2008

Target shares issued through a directed issue of shares and a commercial milestone payment of a total of USD 6 million (approximately DKK 28.3 million), which is defined as 10% of the first USD 60 million (approximately DKK 283.5 million) of belinostat sales or partnership revenues.

Belinostat is currently being tested in 18 clinical trials (10 sponsored by the NCI) to treat different types of cancer. Belinostat is safe and well-tolerated also when combined with chemotherapy, and has the unique flexibility of being administered both intravenously and orally in capsule form. This differentiates belinostat from its competitors. In 2007, the product was included in Windhover Information's top ten of the most interesting cancer products for partnering.

"TopoTarget will now push forward the development of belinostat to benefit cancer patients and will focus on bringing the drug to the market as soon as possible. Today's deal represents a great opportunity for TopoTarget and its shareholders by gaining sole ownership of belinostat. We can now pursue an initial registration in PTCL using our in house proven clinical and regulatory team and focus on pursuing a partnership with a large pharma which has the development and commercialisation muscle to exploit belinostat's blockbuster potential," said Peter Buhl Jensen, CEO of TopoTarget.

TopoTarget's belinostat strategy TopoTarget will now focus its resources on the development of belinostat, and the company has initiated a reorganisation to reflect this focus. In the second half of this year TopoTarget expects to launch the first registration trial in PTCL, a disease where no standard treatment is approved. TopoTarget is also pursuing a fast track status and an orphan drug status for this indication. With clinical trials commencing in the second half of 2008, TopoTarget believes a market approval could be obtained in 2010.

TopoTarget also expects to pursue a development programme in ovarian cancer
'/>"/>

SOURCE TopoTarget A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
2. Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period
3. SBT Acquisition Inc. Successfully Completes Tender Offer for Shares of Lifecore Biomedical, Inc.
4. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
5. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
6. Life on Mars pregnancy test successfully launched
7. EpiStem Successfully Complete First Year of Mucositis Tests for NIH Biodefence Programme
8. ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc.
9. Citrate appears to control buckyball clumping but environmental concerns remain
10. Vela Laboratories Receives the GMP Certificate for Its Analytical and Quality Control Laboratories
11. CSC Continues Support of Centers for Disease Control and Prevention Through New Task Order
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... ... Ralco is honored to announce that it is the primary sponsor of ... 5-9 in Marshall. The Ralco Enrichment Center is an interactive experience where the public ... daily lives. This unique exhibit also features a birthing center for fair goers to ...
(Date:7/30/2015)... USA (PRWEB) , ... July 30, 2015 , ... ... microsystems, has appointed Francois Vieillard as Sales & Marketing Director. , With ... Francois Vieillard will be responsible for reinforcing Tronics’ business development activities worldwide. He ...
(Date:7/30/2015)... ... July 30, 2015 , ... Leading ... clinical study of its canine osteoarthritis stem cell product, currently under development for ... KS) and will be marketed in the US by Aratana. This product, termed ...
(Date:7/30/2015)... , July 30, 2015  With over 60,000 customers across the globe, ISN improves ... 450 hiring organizations with more than 60,000 safe and reliable contractors in over 80 countries. ... ... Over ... Headquartered in Dallas, TX ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3
... hurdle using Star-P, WALTHAM, Mass., Feb. ... Architecture Research Lab (NUCAR) and the National,Science ... Imaging,Systems (CenSSIS) are teaming with Massachusetts General ... detection technology that improves breast,cancer screening accuracy. ...
... (Nasdaq: NPSP ) announced today that Dr. Tony ... chief executive,officer and a director effective March 17, 2008 ... Onyx Pharmaceuticals, Inc. (Nasdaq:,ONXX). He will be succeeded by ... Nader, who will become president and chief,executive officer of ...
... (OTC,Bulletin Board: SNKTY), a Life Sciences company engaged in ... aging, today announced,that results of a clinical study of ... Journal of Drugs in Dermatology., The study was ... over 12 weeks for improving the baseline clinical,signs and ...
Cached Biology Technology:Northeastern University and Mass General Hospital Increase the Accuracy, While Reducing the Diagnosis Time, for Breast Cancer Detection 2Northeastern University and Mass General Hospital Increase the Accuracy, While Reducing the Diagnosis Time, for Breast Cancer Detection 3NPS Pharmaceuticals Announces Senior Management Changes 2NPS Pharmaceuticals Announces Senior Management Changes 3Pyratine-6(TM) Study Published in Journal of Drugs in Dermatology 2Pyratine-6(TM) Study Published in Journal of Drugs in Dermatology 3
(Date:7/31/2015)... 31 juillet 2015 La 10e Conférence ... sera organisée par le BGI du 22 au ... en Chine. La conférence célèbre ... en 2006, l,ICG est devenue l,une des réunions ... des « omiques » et c,est aussi la plus dynamique, ...
(Date:7/31/2015)... Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... filed provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY ... a method to advance crypto-currencies such as Bitcoin into ... common, uniform way to manage all payments.  ...
(Date:7/27/2015)... Calif. , July 27, 2015  Synaptics ... of human interface solutions, today announced that Huawei ... touchscreen solution for its stylish smartwatch. Huawei ... its proven reliability, low power and highly responsive ... wet finger. Huawei designers also required a classic ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... two-dozen countries have signed a consensus statement on the ... as the most serious and pervasive include overfishing, pollution, ... "This is first time the scientific ... express urgency over the environmental crisis facing the Pacific ...
... feeding frenzy that played out 73 million years ago ... of new dinosaur species in northwestern Alberta. University ... paleontology graduate student from Italy, made the discovery near ... Miyashita and Fanti came across a nesting site and ...
... Rare traits persist in a population because predators detect common ... access journal BMC Ecology found that birds will ... their behavior in response to alterations in the ratio of ... of Tennessee, worked with Kim Shook and Reuben Izally to ...
Cached Biology News:Scientists urge world leaders to respond cooperatively to Pacific Ocean threats 2New dinosaur species possible in Northwestern Alberta 2
The LIC Duet™ Mini Adaptor encodes a T7 promoter, lac operator, ribosome binding site (rbs), and an ATG translation initation codon. This adaptor is designed for expression of a target protei...
... scale-up, these culture chambers produce cell yields ... range and are useful alternatives to ... High mechanical • strength and structural integrity ... • Certified nonpyrogenic and sterilized by gamma ...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
...
Biology Products: